Tables.

Table E1.

Mouse miRNAs up-regulated in the Ag-affinity column Eluate (ETX) compared to the Flow Through (FTX) in order of frequency Flow TNP-Ts Sup (thus anti-TNP) nanovesicles applied to the TNP-Ag linked column and Flow Through (FTX) the column vs eluate TNP-Ts Sup exosome-like nanovesicles binding the column frequencies = number of sequence reads/total reads in the sample; i.e. here, miRNA sequences more frequent in the Eluate vs. the Flow Through.

logConc: overall concentration for a miRNA across the two groups being compared

logFC: log-fold change for the counts between the groups. The p-values were adjusted for multiple testing, using the Benjamini and Hochberg's approach for controlling the false discovery rate (FDR). p value: the exact p-values computed by edgeR.

Table E2. Mouse miRNAs up-regulated in Ag-affinity column Flow Through (FTX) compared to the Eluate (ETX) in order of frequency. Shown here are miRNA sequences more frequent in the Flow Through vs the Eluate.

Supplemental Table 1. Mouse miRNAs significantly up-regulated in the TNP Ag-affinity column Elute (ETX) compared to the Flow Through (FTX). Log(concentration) indicates the overall concentration for a miRNA across the two groups, Log (fold-change) indicates the log-fold change for the normalized counts (ETX/FTX), P-Value indicates the significance (computed by edgeR) when comparing the concentrations from the ETX and FTX groups, FDR (False Discovery Rate) indicates the P-Value after adjusting for multiple testing using the Benjamini and Hochberg approach, # Reads FTX and EXT indicate the number of reads for each group.

mmu-mir	Log (concentration)	Log (fold-change)	P-value	FDR	# Reads FTX	# Reads ETX
mmu-mir-92a-1	-12.70	5.79	1.76E-12	3.19E-10	60	457
mmu-mir-33	-16.44	8.13	3.41E-12	3.19E-10	2	77
mmu-mir-27a	-15.36	5.96	1.89E-10	1.18E-08	9	77
mmu-mir-484	-16.19	6.00	7.51E-10	3.51E-08	5	44
mmu-mir-296	-31.74	36.54	5.26E-09	1.40E-07	0	36
mmu-mir-92a-2	-17.20	6.62	7.60E-08	1.78E-06	2	27
mmu-mir-150	-13.11	3.69	8.95E-07	1.67E-05	94	167
mmu-mir-210	-17.95	7.11	1.72E-06	2.52E-05	1	19
mmu-mir-486	-17.95	7.11	1.72E-06	2.52E-05	1	19
mmu-let-7b	-13.83	3.54	2.94E-06	3.67E-05	60	96
mmu-mir-184	-32.29	35.46	5.19E-06	6.06E-05	0	17
mmu-let-7i	-11.32	3.17	9.88E-06	1.09E-04	389	479
mmu-mir-423	-14.17	3.39	1.15E-05	1.19E-04	50	72
mmu-mir-500	-32.48	35.07	4.53E-05	4.46E-04	0	13
mmu-mir-153	-32.60	34.83	1.65E-04	1.47E-03	0	11
mmu-mir-328	-17.78	4.28	1.01E-03	8.55E-03	3	8
mmu-mir-222	-16.38	3.09	1.18E-03	9.56E-03	12	14
mmu-mir-1964	-32.83	34.37	1.41E-03	1.10E-02	0	8
mmu-mir-221	-15.31	2.50	2.35E-03	1.69E-02	31	24
mmu-mir-339	-17.42	3.54	4.07E-03	2.53E-02	5	8
mmu-mir-147	-33.04	33.96	6.15E-03	3.38E-02	0	6
mmu-mir-98	-18.12	3.60	9.22E-03	4.93E-02	3	5

Supplemental Table 2. Mouse miRNAs significantly up-regulated in the TNP Ag-affinity column Flow Through (FTX) compared to the Elute (ETX). For column descriptions, please see Supplemental Table 1 caption.

mmu-mir	Log (concentration)	Log (fold-change)	P-value	FDR	# Reads FTX	# Reads ETX
mmu-mir-29a	-10.63	-4.74	9.81E-10	3.67E-08	9766	50
mmu-mir-148a	-13.75	-5.14	5.23E-09	1.40E-07	1288	5
mmu-mir-26b	-12.99	-3.90	8.93E-07	1.67E-05	1411	13
mmu-mir-148b	-15.89	-5.51	1.76E-06	2.52E-05	333	1
mmu-mir-340	-16.00	-5.29	2.88E-06	3.67E-05	285	1
mmu-mir-696	-32.48	-35.08	1.60E-04	1.47E-03	95	0
mmu-mir-2133-2	-14.35	-2.59	1.90E-03	1.42E-02	350	8
mmu-mir-20a	-15.55	-3.01	2.47E-03	1.71E-02	176	3
mmu-mir-29c	-16.74	-3.81	3.49E-03	2.33E-02	102	1
mmu-mir-191	-15.03	-2.58	3.82E-03	2.46E-02	218	5
mmu-mir-712	-14.49	-2.30	5.10E-03	3.07E-02	287	8
mmu-mir-155	-33.10	-33.83	5.48E-03	3.10E-02	40	0
mmu-mir-362	-33.10	-33.83	5.48E-03	3.10E-02	40	0

Supplemental Figure 1



Repository E Figure No. 2



Supplemental Figure 3

a



b

Group (5 mice/gp)	Prior to transfer TNP CS-effector cells treated with Exosome-like Nanovesicles from	Route of transfer of Nanovesicle	Net Adoptive TNP Transferred CS-Response (mm × 10^{-2} ± SE)	% positive control	% sup-pression
A	CS-effector cells alone (positive control)	none	p<0.001	100	0
B	TNP-Ts Sup	*i.p.*	p<0.01 p<0.01	33	67
C	TNP-Ts Sup	*i.v.*		74	26
D	TNP-Ts Sup	oral		80	20

Supplemental Figure 4

Group (5 mice/gp)	Mouse source of TNP-Ts Sup vesicles	Prior to transfer nanovesicles treated with	24 hr TNP Adoptive CS Ear Swelling Response (mm × 10^{-2} ± SE)	% positive control	% sup-pression
A	–	–		100	0
B	$JH^{-/-}$ Ts Sup	–		116	0
C	$JH^{-/-}$ Ts Sup	Anti-TNP Ig free LC (2μg)		37	63
D	$JH^{-/-}$ Ts Sup	Anti-TNP Ig free HC (8 μg)		135	0
E	$JH^{-/-}$ Ts Sup	Anti-TNP Ig free HC (16 μg)		129	0
F	Wild type TNP Ts Sup	–		60	40
G	NI Cell Sup	–		115	0